X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Abbott India with Torrent Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ABBOTT INDIA vs TORRENT PHARMA - Comparison Results

ABBOTT INDIA    Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

TORRENT PHARMA 
   Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ABBOTT INDIA TORRENT PHARMA ABBOTT INDIA/
TORRENT PHARMA
 
P/E (TTM) x 38.7 36.9 104.8% View Chart
P/BV x 11.2 5.7 194.5% View Chart
Dividend Yield % 0.5 0.9 57.8%  

Financials

 ABBOTT INDIA   TORRENT PHARMA
EQUITY SHARE DATA
    ABBOTT INDIA
Mar-17
TORRENT PHARMA
Mar-17
ABBOTT INDIA/
TORRENT PHARMA
5-Yr Chart
Click to enlarge
High Rs5,1901,768 293.6%   
Low Rs4,3511,186 367.0%   
Sales per share (Unadj.) Rs1,382.9346.1 399.6%  
Earnings per share (Unadj.) Rs130.255.2 236.0%  
Cash flow per share (Unadj.) Rs137.973.3 188.1%  
Dividends per share (Unadj.) Rs40.0014.00 285.7%  
Dividend yield (eoy) %0.80.9 88.4%  
Book value per share (Unadj.) Rs652.7257.1 253.9%  
Shares outstanding (eoy) m21.25169.22 12.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.44.3 80.9%   
Avg P/E ratio x36.626.8 136.9%  
P/CF ratio (eoy) x34.620.1 171.7%  
Price / Book Value ratio x7.35.7 127.2%  
Dividend payout %30.725.4 121.1%   
Avg Mkt Cap Rs m101,373249,887 40.6%   
No. of employees `0003.111.8 26.2%   
Total wages/salary Rs m3,4539,934 34.8%   
Avg. sales/employee Rs Th9,531.94,971.5 191.7%   
Avg. wages/employee Rs Th1,119.9843.2 132.8%   
Avg. net profit/employee Rs Th897.3792.4 113.2%   
INCOME DATA
Net Sales Rs m29,38758,569 50.2%  
Other income Rs m5762,233 25.8%   
Total revenues Rs m29,96360,802 49.3%   
Gross profit Rs m3,97313,773 28.8%  
Depreciation Rs m1643,069 5.4%   
Interest Rs m202,056 1.0%   
Profit before tax Rs m4,36510,881 40.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,5981,545 103.4%   
Profit after tax Rs m2,7679,336 29.6%  
Gross profit margin %13.523.5 57.5%  
Effective tax rate %36.614.2 257.9%   
Net profit margin %9.415.9 59.1%  
BALANCE SHEET DATA
Current assets Rs m18,90653,841 35.1%   
Current liabilities Rs m6,29731,612 19.9%   
Net working cap to sales %42.938.0 113.0%  
Current ratio x3.01.7 176.3%  
Inventory Days Days6297 64.0%  
Debtors Days Days2284 25.8%  
Net fixed assets Rs m1,15942,079 2.8%   
Share capital Rs m213846 25.1%   
"Free" reserves Rs m13,65742,655 32.0%   
Net worth Rs m13,86943,501 31.9%   
Long term debt Rs m022,408 0.0%   
Total assets Rs m20,638101,250 20.4%  
Interest coverage x215.06.3 3,415.8%   
Debt to equity ratio x00.5 0.0%  
Sales to assets ratio x1.40.6 246.2%   
Return on assets %13.511.3 120.0%  
Return on equity %19.921.5 92.9%  
Return on capital %31.619.6 161.1%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m020,066 0.0%   
Fx outflow Rs m05,304 0.0%   
Net fx Rs m014,762 0.0%   
CASH FLOW
From Operations Rs m3,07210,127 30.3%  
From Investments Rs m-1,554-7,869 19.7%  
From Financial Activity Rs m-898-1,918 46.8%  
Net Cashflow Rs m621212 293.4%  

Share Holding

Indian Promoters % 0.0 71.5 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 7.9 7.0 112.5%  
FIIs % 0.1 12.6 0.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.1 8.8 194.3%  
Shareholders   18,270 26,511 68.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ABBOTT INDIA With:   SUVEN LIFE  SHASUN PHARMA  PIRAMAL ENTERPRISES  TTK HEALTHCARE  SUN PHARMA  

Compare ABBOTT INDIA With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Volatile Day in Red; Pharma Stocks Lose Most(Closing)

After opening the day in green, share markets in India witnessed volatile trading activity throughout the day and ended the day on a negative note.

Related Views on News

TORRENT PHARMA Announces Quarterly Results (4QFY18); Net Profit Up 10.7%

Jun 1, 2018 | Updated on Jun 1, 2018

For the quarter ended March 2018, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 10.7% YoY). Sales on the other hand came in at Rs 17 bn (up 20.1% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

After Vakrangee and Manpasand, More Auditors May Soon Resign. To Protect Your Wealth, Avoid these Stocks(The 5 Minute Wrapup)

Jun 8, 2018

The change in auditing regulations can bring a big change in corporate governance behaviour in the mid and small-cap space.

Alert: Pharma Stocks Are About to Shoot Up - And a Superb Stock for Trading(Profit Hunter)

Jun 13, 2018

The ailing pharma stocks are bouncing back to health. Read this to find out the best way to profit from them.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Is Data Pointing Towards a Revival in the FMCG Sector?(Sector Info)

Jun 8, 2018

After several quarters of stress in the aftermath of demonetisation and the rollout of GST, this data is pointing towards revival in the India's rural FMCG industry.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ABBOTT INDIA SHARE PRICE


Jun 21, 2018 (Close)

TRACK ABBOTT INDIA

  • Track your investment in ABBOTT INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ABBOTT INDIA - GSK PHARMA COMPARISON

COMPARE ABBOTT INDIA WITH

MARKET STATS